Lara Marilis T, Gurgel-Giannetti Juliana, Aguiar Marcos J B, Ladeira Roberto V P, Carvalho Nara O, Del Castillo Dora M, Viana Marcos B, Januario José N
UFMG University Hospital, NUPAD - Center for Newborn Screening and Genetic Diagnostics, UFMG Federal University of Minas Gerais, Belo Horizonte, Brazil.
Department of Pediatrics, NUPAD - Center for Newborn Screening and Genetic Diagnostics, UFMG Federal University of Minas Gerais, Belo Horizonte, Brazil.
JIMD Rep. 2015;24:103-7. doi: 10.1007/8904_2015_447. Epub 2015 May 13.
To assess the incidence of biotinidase deficiency among newborns and their clinical outcome up to one year of age in a large pilot screening study in Minas Gerais, Brazil.
A prospective cohort study was conducted from September 2007 to June 2008 with heel-prick blood samples collected on filter paper for the purpose of newborn screening. A qualitative colorimetric test was used as the primary screening method. Colorimetric-positive cases were further tested with a serum confirmatory assay. Gene sequencing was performed for eight children suspected with biotinidase deficiency and for some of their parents. Positive cases were daily supplemented with oral biotin and were followed up for approximately six years.
Out of 182,891 newborns screened, 129 were suspected of having biotinidase deficiency. Partial deficiency was confirmed in seven children (one was homozygous for p.D543E) and profound deficiency in one child (homozygous p.H485Q). Thus the incidence was one in 22,861 live births (95% confidence interval 1:13,503 to 1:74,454) for profound and partial biotinidase deficiency combined. Two novel mutations were detected: p.A281V and p.E177K. In silico analysis and estimation of the enzyme activity in the children and their parents showed that p.A281V is pathogenic and p.E177K behaves like p.D444H.
The incidence of biotinidase deficiency in newborn screening in Minas Gerais was higher than several international studies. The sample size should be larger for final conclusions. Oral daily biotin apparently precluded clinical symptoms, but it may have been unnecessary in some newborns.
在巴西米纳斯吉拉斯州的一项大型试点筛查研究中,评估新生儿生物素酶缺乏症的发病率及其一岁以内的临床结局。
2007年9月至2008年6月进行了一项前瞻性队列研究,采集足跟血样于滤纸上用于新生儿筛查。采用定性比色法作为初筛方法。比色法呈阳性的病例进一步用血清确证试验检测。对8名疑似生物素酶缺乏症的儿童及其部分父母进行基因测序。阳性病例每日口服补充生物素,并随访约6年。
在182,891名接受筛查的新生儿中,129名疑似患有生物素酶缺乏症。7名儿童被确诊为部分缺乏(1名p.D543E纯合子),1名儿童被确诊为严重缺乏(p.H485Q纯合子)。因此,严重和部分生物素酶缺乏症合并的发病率为每22,861例活产中有1例(95%置信区间1:13,503至1:74,454)。检测到两个新的突变:p.A281V和p.E177K。对儿童及其父母的计算机分析和酶活性估计表明,p.A281V具有致病性,p.E177K的表现与p.D444H相似。
米纳斯吉拉斯州新生儿筛查中生物素酶缺乏症的发病率高于几项国际研究。要得出最终结论,样本量应更大。每日口服生物素显然可预防临床症状,但在一些新生儿中可能并无必要。